Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia

NCT03789760 is registered in ClinicalTrials.gov with Shineway Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT03789760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03789760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia
Lead sponsor
Shineway Pharmaceutical Co.,Ltd
Phase
Phase 3
Overall status
Completed
Start date
April 10, 2019
Completion date
May 19, 2024
Enrollment
493 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

vascular dementia